



BA-BCS 2024 PROGRAM

TUESDAY, SEPTEMBER 3

15:00-17:45 Registration

17:45-18:00 Welcome from organizers

18:00-19:00 **Opening Conference**

Chairs: Claudia Lanari, IBYME-CONICET, Buenos Aires, Argentina and Edith Kordon, IFIBYNE-UBA-CONICET, Buenos Aires, Argentina.

Robert Clarke, University of Manchester, Manchester, UK.

The role of cytokines in regulating cancer stem cells in therapy-resistance and metastasis.

19:00: Welcome Reception at IFIBYNE

WEDNESDAY, SEPTEMBER 4

9:30-11:00/ Session 1: Luminal breast cancer

Chairs: Caroline Lamb, IBYME-CONICET, Buenos Aires, Argentina and María F. Rubio, IDIM-UBA-CONICET, Buenos Aires, Argentina.

9:30-10:00 **Todd Miller**, Medical College of Wisconsin Cancer Center, Milwaukee, USA.
Leveraging endocrine and metabolic vulnerabilities in ER+ breast cancer.

10:00-10:30 **Joseph Jerry**, University of Massachusetts, Amherst, USA.
A panel of normal breast epithelial cells from donors differing in breast cancer risk: variation in barriers to immortalization and estrogen signaling.

10:30-10:45 **Abstract selected for oral presentation:** RUNX2 expression correlates with tumor progression in luminal breast cancer patients. Yamil D Mahmoud, IBYME-CONICET, Buenos Aires, Argentina.

10:45-11:00 **Discussion**

11:00-11:30 **Coffee Break and Posters**



**BUENOS AIRES
BREAST CANCER
SYMPOSIUM** 2024

11:30-13:00 / Session 2: New treatments for Luminal and Her2+ breast cancer

Chairs: Natalia Rubinstein, iB3, FCEyN, UBA, Buenos Aires, Argentina and Vanina Medina, BIOMED-CONICET, UCA, Buenos Aires, Argentina.

11:30-12:00 **Jennifer Richer**, University of Colorado, Aurora, USA.
AR action in ER+ breast cancer – preclinical and clinical trial updates.

12:00-12:30 **Federico Waisberg**, Instituto Fleming, Buenos Aires, Argentina.
New treatments and biomarkers in hormone resistant (HR+) breast cancer.

12:30-12:45 **Abstract selected for oral presentation:** Inhibition of Rac1 activity enhances Tostuzumab sensitivity in Her2-positive breast cancer cells through cell cycle deregulation, Virginia Judith Wolos, Instituto de Oncología Ángel Roffo, Buenos Aires, Argentina.

12.45-13:00 **Discussion**

13:00-15:00 / Lunch and Posters

14:40-15:00 Sponsor presentation: LOBOV Científica

15:00-17:00 / Session 3: Detection and treatment of TNBC

Chairs: Roxana Schillaci, IBYME-CONICET, Buenos Aires, Argentina and Maria José Rico, Facultad de Ciencias Médicas, UNR, Rosario, Argentina.

15:00-15:30 **Roger Chammas**, Center for Translational Research in Oncology, University of São Paulo, Brazil.
miRNAs as biomarkers for early onset Triple Negative Breast Cancers.

15:30-16:00 **Paolo Ceppi**, University of Southern Denmark, Odense, Denmark.
Propionate suppresses epithelial-to-mesenchymal transition and reduces the aggressiveness of lung carcinoma, can we extrapolate to breast cancer?

16:00-16:30 **Pablo Mandó**, CEMIC, Buenos Aires, Argentina.
New therapeutic options for TNBC.

16:30-16:45: **Abstract selected for oral presentation:** Enhancing Paclitaxel efficacy in triple negative breast cancer through DKC1 inhibition with R1D2-10, Roman Nicolas Vilarullo, Universidad Nacional de Quilmes, Buenos Aires, Argentina.

16:45-17:00 **Discussion**

17:00-17:30 Coffee break and Posters



17:30-19.00 / Round Table 1 (Spanish)

Coordinadoras: Mariana Salatino, IBYME-CONICET, Buenos Aires, Argentina y María Roqué, IHEM-CONICET, Mendoza, Argentina.

Utilidad clínica de la búsqueda de marcadores circulantes en biopsia líquida, para el redireccionamiento y/o seguimiento de la carga tumoral en pacientes con cáncer de mama.

Adriana De Siervi, IBYME-CONICET y Oncoliq, Buenos Aires, Argentina.

Javier Stigliano, Hospital Nacional Prof. A Posadas, Haedo, Argentina.

Manglio Rizzo, Departamento Oncología, Hospital Universitario Austral, Pilar, Argentina.

Julieta Pandolfi, Anatomía Patológica. Lab. Secuenciación. Hospital Italiano de Buenos Aires, Argentina.

Diego Marzese (participante virtual) Division of Surgical Oncology, Duke University School of Medicine (DUSM), Durham, USA.

THURSDAY, SEPTEMBER 5

9:30-11:15 / Session 4: Cancer Stem Cells and Tumor Initiation

Chairs: Albana Gattelli, IFIBYNE-UBA-CONICET, Buenos Aires, Argentina and Catalina Lodillinski, Instituto Ángel Roffo, Buenos Aires, Argentina.

9:30-10:00 **Fariba Behbod**, University of Kansas, Kansas City, USA.
Ductal carcinoma in situ: Transcriptional diversity and stemness.

10:00-10:30 **Jochen Maurer**, University Hospital RWTH, Aachen, Germany.
Cancer stem cells as disease models in research – opportunities and challenges.

10:30-11:00 **William Muller**, Rosalind and Morris Goodman Cancer Center, Montreal, Canada.
Oncogene-mediated regulation of tumor immune microenvironment in mouse models of human breast cancer

11:00-11:15 **Discussion**

11:15-11:45 **Coffee Break and Posters**



11:45-13:30 / Session 5: Breast Cancer Genomics and Transcriptomics

Chairs: Ignacio Schor, IFIBYNE-UBA-CONICET, Buenos Aires, Argentina and Marianela Candolfi, INBIOMED, FMED, UBA, Buenos Aires, Argentina.

11:45-12:15 **Martin Abba**, UNLP, La Plata, Argentina.
Old questions, new omics tools.

12:15-12:45 **Pedram Razavi**, Memorial Sloan Kettering Cancer Center, New York City, USA.
Breast cancer genomics and resistance to CDK4/6i.

12:45-13:00 **Gonzalo Gomez Abuin**, Hospital Alemán, Buenos Aires, Argentina.
Utility of next generation sequencing in breast cancer.

13:00-13:15 **Abstract selected for oral presentation:** Exploring the effects of non-coding somatic mutations in BAF complex deregulation and the malignant characteristics of triple-negative breast cancer, Pedro J. Salaberry, IFIBYNE-UBA-CONICET, Buenos Aires, Argentina.

13:15-13:30 **Discussion**

13:30-15:00 Lunch and Posters Session 2

15:00-17:00/ Session 6: immunotherapy and fighting treatment resistance

Chairs: Georgina Coló, INIBIBB-UNS, Bahía Blanca, Argentina and Germán A. Gil, CIQUIBIC, UNC-CONICET), Córdoba, Argentina.

15:00-15:30 **Adrian Lee**, University of Pittsburgh, Pittsburgh, USA.
Endocrine resistance in breast cancer metastasis.

15:30-16:00 **Dejan Juric**, Massachusetts General Hospital, Boston, USA.
Novel PI3Ki inhibitors including mutant-selective PI3K inhibitors.

16:00-16:30 **María Vivanco**, CIC bioGUNE, Basque Research and Technology Alliance, Derio, Spain.
Breast Cancer heterogeneity and resistance to hormone therapy.

16:30-16:45 **Abstract selected for oral presentation:** Preclinical and clinical role of MUC4/TNF axis in metastatic triple-negative breast cancer, Florencia Mauro, IBYME-CONICET, Buenos Aires, Argentina.

16:45-17:00 **Discussion**

17:00-17:30 Coffee Break and Posters

E-mail: ba.bcsymposium@gmail.com

Web: <https://ba-bcsymposium.com/>



17:30-19:00 / Round Table 2 (Spanish)

Coordinadores: Mario Rossi Universidad Austral, Pilar, Argentina y Pablo Mandó, CEMIC, Buenos Aires, Argentina

Jerarquización en investigación dentro de la carrera de formación de los médicos, experiencias en CEMIC, Fleming y Austral.

Manglio Rizzo, Servicio de Oncología Hospital Austral, Pilar, Argentina.

Fernando Petracci, Instituto Fleming, Buenos Aires, Argentina.

Estrella Levy, Instituto Fleming, Buenos Aires, Argentina,

20:30-21:30 Tango Concert at Museo Nacional de Ciencias Naturales "Bernardino Rivadavia" (separate registration)

FRIDAY, SEPTEMBER 6

9:30-11:15 / Session 7: Early detection and treatment

Chairs: Giselle Peters, Instituto Ángel Roffo, Buenos Aires, Argentina and Leandro E. Mainetti, Facultad de Ciencias Médicas, UNR, Rosario, Argentina.

9:30-10:00 **Vanesa Gottifredi**, Instituto Leloir, Buenos Aires, Argentina.
Targeting the chromosomal instability induced by cancer therapy.

10.00-10:30 **Cathrine Park**, University of California, San Francisco, USA.
Evolution of breast radiotherapy options for today's early stage patients.

10:30-10:45 **Adriana de Siervi**, Oncoliq, CABA-Argentina.
miRNAs for early cancer detection in liquid biopsy.

10:45-11:00 **Abstract selected for oral presentation:** SPARC: a potential biomarker of the transition from in situ to Invasive breast cancer, Marianela Sciacca, Instituto de Oncología Ángel Roffo, Buenos Aires, Argentina.

11:00-11:15 **Discussion**

11:15-11:45 **Coffee Break and Posters**



**BUENOS AIRES
BREAST CANCER
SYMPOSIUM** 2024

11:45-13:30 / Session 8: Understanding and modeling breast cancer subtypes

Chairs: Paola Rojas, IBYME-CONICET, Buenos Aires, Argentina and María T. Branham, IHEM-CONICET, Mendoza, Argentina.

11:45-12:15 **Steffi Oestereich**, University of Pittsburgh, Pittsburgh, USA.
Invasive lobular breast cancer – what’s different and why is this important?

12:15-12:45 **Alana Welm**, University of Utah, Salt Lake City, Utah, USA.
Using patient-derived models for drug discovery and functional precision oncology in advanced breast cancer.

12:45-13:00 **Abstract selected for oral presentation:** RET receptor integrates tumor cell-adipocyte communication to promote breast cancer. Sabrina A. Vallone, IFIBYNE-UBA-CONICET, Buenos Aires, Argentina.

13:00-13:15 **Abstract selected for oral presentation:** Progesterone promotes triple-negative breast cancer metastasis through RANKL-expressing Treg cells. Tomas Dalotto, IBYME-CONICET, Buenos Aires, Argentina.

13:15-13:30 **Discussion**

13:30-15:00 / Lunch and Posters

15:00-16:00 / Session 9: Improving life quality

Chair: Mario Rossi, Universidad Austral, Pilar, Argentina and Virginia Novaro, IBYME-CONICET, Buenos Aires, Argentina

15:15-15:45 **Sybil Pettit**, Health and Environmental Sciences Institute (HESI), Washington DC, USA.
Addressing Cancer Therapy Related Adverse Effects – An Opportunity to Improve Quality of Life and Outcome for Patients.

15:45-16:00 Discussion

16:00-17:00 / Closing Conference

Chairs: Osvaldo Podhajcer, Instituto Leloir, CONICET, Buenos Aires, Argentina and Mariana Salatino, IBYME-CONICET, Buenos Aires, Argentina.

Katherine Hoadley, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA.

Quantitative Medicine for Breast Cancer Patients.

17:00-17:15 / Discussion and closing remarks by the organizers



BUENOS AIRES
BREAST CANCER
SYMPOSIUM 2024

17:15-17:30 Coffee break

17:30-19:00 / Round Table 3 (Spanish)

Coordinadores: Virginia Novaro, IBYME-CONICET, Buenos Aires, Argentina y Federico Waisberg, Instituto A. Fleming, Buenos Aires, Argentina.

Navegación en el sistema de salud para pacientes con bajo y alto riesgo de cáncer de mama. Situación actual en la región Norte, Centro y Sur del país.

Alejandro Di Sibio coordinador del Programa Nacional de Control de Cáncer de Mama del Instituto Nacional del Cáncer, Buenos Aires, Argentina

Marcela Kober del Instituto Misionero del Cáncer, Posadas, Argentina.

Romina Yapur, Hospital Villa Regina de Río Negro y Centro Oncológico Integral, General Roca, Argentina.